BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 29705511)

  • 1. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 8. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 9. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
    Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
    Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
    Gaultier De Saint Basile H; Poisson C; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Tartour E; De Guillebon E
    Bull Cancer; 2018 Dec; 105(12):1202-1208. PubMed ID: 30471959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
    Hu B; Yang XB; Sang XT
    Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
    Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
    Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
    [No Abstract]   [Full Text] [Related]  

  • 20. PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun F; Rassy EE; Assi T; Kattan J
    Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.